Evidence map›Paper›PMID 37635986›Full record

ArticleFrontiers in endocrinology2023

Risk of thyroid neoplasms in patients with 22q11.2 deletion and DiGeorge-like syndromes: an insight for follow-up.

Walter Maria Sarli, Silvia Ricci, Lorenzo Lodi, Federica Cavone, Lucia Pacillo, Carmela Giancotta, Graziamaria Ubertini, Giampiero Baroncelli, Caterina Cancrini, Chiara Azzari and 1 more

Open access · goldAbstract readCase ReportsMulticenter Study
In one paragraph

Article in Frontiers in endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Walter Maria SarliDepartment of Health Sciences, University of Florence, Florence, Italy.
Silvia RicciDepartment of Health Sciences, University of Florence, Florence, Italy.
Lorenzo LodiDepartment of Health Sciences, University of Florence, Florence, Italy.
Federica CavonePediatrics Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Lucia PacilloUnit of Clinical Immunology and Vaccinology, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.
Carmela GiancottaUnit of Clinical Immunology and Vaccinology, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.
Graziamaria UbertiniUnit of Endocrinology and Diabetology, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.
Giampiero BaroncelliPediatrics Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Caterina CancriniUnit of Clinical Immunology and Vaccinology, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.
Chiara AzzariDepartment of Health Sciences, University of Florence, Florence, Italy.
Stefano StagiDepartment of Health Sciences, University of Florence, Florence, Italy.
Istituti di Ricovero e Cura a Carattere Scientifico · ITUniversity of Florence · ITMeyer Children's Hospital · ITUniversity of Pisa · ITBambino Gesù Children's Hospital · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The chromosome 22q11.2 deletion syndrome comprises phenotypically similar diseases characterized by abnormal development of the third and fourth branchial arches, resulting in variable combinations of congenital heart defects, dysmorphisms, hypocalcemia, palatal dysfunction, developmental or neuropsychiatric disorders, and impairment of the immune system due to thymic dysfunction. Other genetic syndromes, often called DiGeorge-like, share clinical and immunological features with 22q11.2 deletion syndrome. This syndrome has been rarely associated with malignancies, mainly hematological but also hepatic, renal, and cerebral. Rarely, malignancies in the head and neck region have been described, although no aggregate of data on the development of thyroid neoplasms in patients with this clinical phenotype has been conducted so far. Materials and methods: To characterize this possible association, a multicenter survey was made. Thus, we present a case series of five pediatric patients with 22q11.2 deletion syndrome or DiGeorge-like syndrome who were occasionally found with confirmed or highly suspected neoplasms of the thyroid gland during their follow-up. In three cases, malignancies were histologically confirmed, but their outcome was good due to an early recognition of suspicious nodules and precocious surgery. Conclusions: This study underlines for clinicians the higher risk of neoplasms in the head and neck district for patients affected by these syndromes. It also emphasizes the importance of a prolonged clinical and ultrasound follow-up for patients with this clinical and immunological phenotype.

Indexed as

DiGeorge SyndromeThyroid NeoplasmsFollow-Up StudiesHumansNeck22q11 deletion syndromeDiGeorgegenetic syndromethyroid cancerthyroid nodules

Identifiers

PMID37635986
PMCPMC10450035
OpenAlexW4385728484

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.